The Fast Track designation is supported by data from the open-label phase 1 SNK01-MX04 trial, as well as preliminary data from the phase 1 cohort from the phase 1/2a SNK01-AD01 trial.

Doug Whitney was supposed to develop Alzheimer's by 50. Now scientists are trying to understand why his brain remains healthy ...

Treatments that don’t involve drugs are also available. These may include talking therapies to help with depression or anxiety, and different forms of treatment (such as cognitive stimulation therapy) ...